National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 40861-40862 [2021-16160]
Download as PDF
<![CDATA[
40861
Federal Register / Vol. 86, No. 143 / Thursday, July 29, 2021 / Notices
ANNUALIZED BURDEN HOUR TABLE
Average
burden per
response
Total burden
hours
Subpart B, § 46.207 .........................................................................................
Subpart C, § 46.306 (iii) and (iv) ......................................................................
Subpart D, § 46.407 .........................................................................................
3
3
4
1
1
1
1
1
1
3
3
4
Total ..........................................................................................................
........................
........................
........................
10
Sherrette A. Funn,
Paperwork Reduction Act Reports Clearance
Officer, Office of the Secretary.
[FR Doc. 2021–16159 Filed 7–28–21; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Advisory Committee on
Blood and Tissue Safety and
Availability
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
The U.S. Department of
Health and Human Services is hereby
giving notice that the Advisory
Committee on Blood and Tissue Safety
and Availability (ACBTSA) will hold a
virtual meeting. The meeting will be
open to the public. The committee will
discuss recommendations to improve
the supply chain and data infrastructure
that supports the blood industry,
especially during public health
emergencies. To facilitate this
discussion, key stakeholders from across
the nation and around the world will
present on hemovigilance,
preparedness, inventory management
systems and other relevant issues.
DATES: The meeting will take place
virtually on Tuesday, August 17, 2021
from approximately 10:00 a.m.–6:00
p.m. and Wednesday, August 18, 2021
from approximately 10:00 a.m.–6:00
p.m. Eastern Time (ET). Meeting times
are tentative and subject to change. The
confirmed times and agenda items for
the meeting will be posted on the
ACBTSA web page at https://
www.hhs.gov/oidp/advisory-committee/
blood-tissue-safety-availability/
meetings/2021-08-17/ when
this information becomes available.
FOR FURTHER INFORMATION CONTACT:
James Berger, Designated Federal Officer
for the ACBTSA; Office of Infectious
Disease and HIV/AIDS Policy, Office of
the Assistant Secretary for Health,
Department of Health and Human
SUMMARY:
VerDate Sep<11>2014
19:19 Jul 28, 2021
Jkt 253001
Services, Mary E. Switzer Building, 330
C Street SW, Suite L600, Washington,
DC 20024. Email: ACBTSA@hhs.gov.
ACBTSA
is a discretionary Federal advisory
committee. ACBTSA The Committee is
governed by the provisions of the
Federal Advisory Committee Act
(FACA), Public Law 92–463, as
amended (5 U.S.C. App), which sets
forth standards for the formation and
use of advisory committees. On the day
of the meeting, please go to https://
www.hhs.gov/live/ to view
the meeting. The public will have an
opportunity to present their views to the
ACBTSA orally during the meeting’s
public comment session or by
submitting a written public comment.
Comments should be pertinent to the
meeting discussion. Persons who wish
to provide verbal or written public
comment should review instructions at
https://www.hhs.gov/oidp/advisorycommittee/blood-tissue-safetyavailability/meetings/2021-08-17/
index.html and respond by midnight
August 9, 2021, ET. Verbal comments
will be limited to three minutes each to
accommodate as many speakers as
possible. Written public comments will
be accessible to the public on the
ACBTSA web page prior to the meeting.
ACBTSA functions to provide advice
to the Secretary through the Assistant
Secretary for Health on a range of policy
issues to include: (1) Identification of
public health issues through
surveillance of blood and tissue safety
issues with national survey and data
tools; (2) identification of public health
issues that affect availability of blood,
blood products, and tissues; (3) broad
public health, ethical, and legal issues
related to the safety of blood, blood
products, and tissues; (4) the impact of
various economic factors (e.g., product
cost and supply) on safety and
availability of blood, blood products,
and tissues; (5) risk communications
related to blood transfusion and tissue
transplantation; and (6) identification of
infectious disease transmission issues
for blood, organs, blood stem cells and
tissues. The Committee has met
SUPPLEMENTARY INFORMATION:
BILLING CODE 4150–36–P
jbell on DSKJLSW7X2PROD with NOTICES
Number of
responses per
respondents
Number of
respondents
45 CFR part 46—HHS consultation process provision
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
regularly since its establishment in
1997.
Dated: July 23, 2021.
James J. Berger,
Designated Federal Officer, Advisory
Committee on Blood and Tissue Safety and
Availability, Office of Infectious Disease and
HIV/AIDS Policy.
[FR Doc. 2021–16120 Filed 7–28–21; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Implementation Research to Improve Case
Finding, Cascade Screening, and Treatment
for Familial Hypercholesterolemia (FH).
Date: September 2, 2021.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Bethesda, MD 20817 (Virtual Meeting).
Contact Person: Susan Wohler Sunnarborg,
Ph.D., Scientific Review Officer, Office of
Scientific Review/DERA, National Heart,
Lung, and Blood Institute, National Institutes
of Health, 6705 Rockledge Drive, Room 208–
Z, Bethesda, MD 20892, (301) 827–7987,
susan.sunnarborg@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
E:\FR\FM\29JYN1.SGM
29JYN1
40862
Federal Register / Vol. 86, No. 143 / Thursday, July 29, 2021 / Notices
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: July 23, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–16160 Filed 7–28–21; 8:45 am]
https://www.nichd.nih.gov/about/
meetings/2021/092321.
Alison N. Cernich,
Deputy Director, Eunice Kennedy Shriver
National Institute of Child Health and Human
Development, National Institutes of Health.
[FR Doc. 2021–16118 Filed 7–28–21; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
Workshop on Exploring the Science
Surrounding the Safe Use of Bioactive
Ingredients in Infant Formula:
Considerations for an Assessment
Framework
National Institutes of Health,
Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
This 2-day, virtual
workshop—Exploring the Science
Surrounding the Safe Use of Bioactive
Ingredients in Infant Formula:
Considerations for an Assessment
Framework—focuses on the functional
state-of-the-science of biologically active
human milk components and analogs
and the implications for safety
assessments when used in infant
formula.
SUMMARY:
The Meeting will be held on
September 23–24, 2021, from 10:30 a.m.
to 4:30 p.m. (ET).
ADDRESSES: This workshop will be
videocast at https://videocast.nih.gov.
FOR FURTHER INFORMATION CONTACT: For
information concerning this meeting,
contract Dr. Ashley Vargas, Pediatric
Growth and Nutrition Branch, Division
of Extramural Research, Eunice Kennedy
Shriver National Institute of Child
Health and Human Development, 6701B
Rockledge Drive, Room 2423C,
Bethesda, MD 20817, telephone: 301–
827–6030, email: ashley.vargas@
nih.gov.
DATES:
This
Federal Register notice is in accordance
with 42 U.S.C. 285g, of the Public
Health Service Act, as amended. This
workshop is led by the Eunice Kennedy
Shriver National Institute of Child
Health and Human Development
(NICHD), the National Institutes of
Health (NIH) Office of Dietary
Supplements (ODS), and the Food and
Drug Administration (FDA). The
workshop is free and open to the public.
The workshop will be livestreamed, and
the video will be archived. Registration
will be available for this meeting at
jbell on DSKJLSW7X2PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
19:19 Jul 28, 2021
Jkt 253001
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; IMAT
Biospecimen Research.
Date: September 30, 2021.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W246, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Jun Fang, Ph.D., Scientific
Review Officer, Research Technology and
Contract Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W246, Rockville, Maryland 20850,
240–276–5460, jfang@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–2: NCI
Clinical and Translational Cancer Research.
Date: October 20–21, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W264, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Ombretta Salvucci, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W264, Rockville,
Maryland 20850, 240–276–7286, salvucco@
mail.nih.gov.
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
Name of Committee: National Cancer
Institute Initial Review Group; Transition to
Independence Study Section (I).
Date: October 20–21, 2021.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W602, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Delia Tang, M.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W602, Rockville, Maryland 20850,
240–276–6456, tangd@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–3: NCI
Clinical and Translational Cancer Research.
Date: October 21–22, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W102, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Shuli Xia, Ph.D., Scientific
Review Officer, Research Technology and
Contract Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W102, Rockville, Maryland 20850,
shuli.xia@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–8: NCI
Clinical and Translational Cancer Research.
Date: November 4–5, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W126, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Susan Lynn Spence, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W126, Rockville, Maryland
20850, susan.spence@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–4: NCI
Clinical and Translational Cancer Research.
Date: November 4–5, 2021.
Time: 11:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W254, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Eduardo Emilio Chufan,
Ph.D., Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W254, Rockville, Maryland
20850, 240–276–7975, chufanee@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
E:\FR\FM\29JYN1.SGM
29JYN1
]]>Agencies
[Federal Register Volume 86, Number 143 (Thursday, July 29, 2021)]
[Notices]
[Pages 40861-40862]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-16160]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; Implementation Research to Improve Case
Finding, Cascade Screening, and Treatment for Familial
Hypercholesterolemia (FH).
Date: September 2, 2021.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Susan Wohler Sunnarborg, Ph.D., Scientific
Review Officer, Office of Scientific Review/DERA, National Heart,
Lung, and Blood Institute, National Institutes of Health, 6705
Rockledge Drive, Room 208-Z, Bethesda, MD 20892, (301) 827-7987,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
[[Page 40862]]
Diseases Research; 93.839, Blood Diseases and Resources Research,
National Institutes of Health, HHS)
Dated: July 23, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-16160 Filed 7-28-21; 8:45 am]
BILLING CODE 4140-01-P
